CH
Coherus Oncology, Inc.
CHRS · NASDAQ
$1.33 -3.48% (-$0.05)
1M +10.83%
Market Cap $211.7M
P/E Ratio -
Div. Yield -
ROE 181.73%
Bulios Fair Price
$1.53
15.0% upside
Current Price
$1.33
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CHRS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
51 /100
Fair P/S 4.16x
P/B 3.48x
P/E N/A
Growth
0 /100
Declining Rev. growth 41.54%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 63.55%
Net margin 257.10%
Op. margin 307.44%
Quality
3 /100
Poor ROIC 135.38%
ROE 181.73%
ROA 68.50%
Debt
55 /100
Moderate Debt/Equity 0.62x
Current ratio 1.77x
Int. coverage -16.74x
Stability
25 /100
Unstable Beta 0.94x
Rev. volatility 56.75%
EPS volatility 435.47%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CHRS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Dennis Lanfear
Employees
144
Headquarters
Redwood City
Upcoming events
05 NOV
Earnings
Upcoming earnings report